Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterGlobeNewsWire • 09/03/24
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 09/02/24
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/14/24
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 07/25/24
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsGlobeNewsWire • 06/26/24
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to BuyZacks Investment Research • 06/06/24
Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingGlobeNewsWire • 06/04/24
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesGlobeNewsWire • 05/02/24
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 04/30/24
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerGlobeNewsWire • 04/01/24
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/19/24
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/13/24
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewsWire • 03/07/24
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceGlobeNewsWire • 02/20/24
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerGlobeNewsWire • 01/30/24
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 01/08/24